TP53 and cancer: In fact, given the high prevalence of mutp53 in PDAC (50–75% of PDAC cases) [64], which is associated with resistance of cancer cells to chemotherapeutic agents by directly compromising BRCA1 shuttling to cytoplasm [65], BBIT20 represents a promising strategy to overcome cancer drug resistance in mutp53 PDAC, by inducing BRCA1 nuclear export (usually mediated by a functional p53) [65].